✦ LIBER ✦

Use of erlotinib in patients selected using clinical criteria in the 2nd and 3rd line treatment of non-small cell lung cancer (NSCLC)

✍ Scribed by Stavridi, F.; Eestila, S.; Merchant, S.; Cane, P.; Spicer, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib treatment results in patients

✍ Salajka, F.; Pešek, M.; Skřičková, J.; Zatloukal, P.; Koubková, L.; Grygárková, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Erlotinib in the first-line treatment of

✍ D’Arcangelo, Manolo ;Cappuzzo, Federico 📂 Article 📅 2013 🏛 Expert Reviews 🌐 English ⚖ 1009 KB

A Phase II Trial of Erlotinib As Front-L

✍ Athanasios G. Pallis; Alexandra Voutsina; Nikolaos Kentepozidis; Stylianos Giass 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 374 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

The Czech Republic experience with erlot

✍ Skřičková, Jana; Bortlíček, Zdeněk; Hejduk, Karel; Pešek, Miloš; Zatloukal, Petr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 46 KB

PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DO

✍ F Negreiro; C Pereira; H Pereira; C Silva 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB